文献速递肝胆胰外科

术前放置胰管支架优化良性胰腺肿瘤剜除术:回顾性队列研究

Optimizing pancreatic enucleation for benign tumors: the role of pre-placed pancreatic duct stents-a retrospective cohort study.
PubMed 文献 · Surg Endosc · 2025-05-05

结果显示术前放置支架显著提高剜除成功率(86.7% vs 28.3%),缩短住院时间,并改善胰腺外分泌功能和生活质量。

要点

  • 术前1–2天经ERCP放置胰管支架可显著提高良性胰腺肿瘤剜除成功率。
  • 支架组腹腔镜手术比例更高、住院时间更短,且不增加并发症或总费用。
  • 支架组胰腺外分泌功能障碍发生率更低,生活质量评分更高。

核心结论

  • 术前放置胰管支架可显著提高剜除成功率、缩短住院时间、保留胰腺功能并改善生活质量,支持在剜除术中应用。

主要发现

  • 支架组剜除成功率86.7%,非支架组28.3%(p=1.763×10-7)。
  • 支架组腹腔镜手术比例86.7%,非支架组41.7%(p=4.9×10-5)。
  • 支架组住院时间中位数7.5天,非支架组11天(p=0.001)。
  • 支架组胰腺外分泌功能障碍发生率10.3%,非支架组35.7%(p=0.016)。
  • 支架组生活质量评分91.2±5.8,非支架组85.5±13.6(p=0.019);术后并发症和总费用无显著差异。

关键数值与推荐

  • 支架组肿瘤与主胰管距离4.2±2.2 mm,非支架组6.2±2.5 mm(p=0.008)。

临床怎么用

  • 对拟行剜除术的胰头、颈、体良性肿瘤患者,可考虑术前1–2天经ERCP放置胰管支架以优化手术结局。

局限性

  • 单中心回顾性设计,样本量有限,结论需进一步前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effectiveness of pre-placed pancreatic duct stents on improving outcomes of pancreatic enucleation for benign tumors, a procedure often discouraged by postoperative complications, such as pancreatic fistulae. METHODS: This single-center retrospective cohort study analyzed 148 patients with benign tumors located in the head, neck, and body of the pancreas between February 2021 and February 2024. Thirty-four patients received stent placement by endoscopic retrograde cholangiopancreatography 1-2 days before surgery, while 114 did not. Propensity score matching resulted in two groups: stent (n = 30) and non-stent (n = 60). Outcomes compared included enucleation success rate, incidence of pancreatic fistulae, hospital stay, procedural costs, pancreatic function deficiency, and quality of life. RESULTS: Pre-placement of stents significantly increased enucleation success rate (86.7% vs. 28.3%, p = 1.763 × 10-7), facilitated more laparoscopic surgeries (86.7% vs. 41.7%, p = 4.9 × 10-5), and shortened hospital stays (median 7.5 days vs. 11 days, p = 0.001). The stent group also showed a lower incidence of pancreatic exocrine dysfunction (10.3% vs. 35.7%, p = 0.016) and higher quality of life scores (91.2 ± 5.8 vs. 85.5 ± 13.6, p = 0.019). No significant differences were observed in postoperative complications or overall costs. Additionally, the distance between tumor and main pancreatic duct was shorter in the stent group (4.2 ± 2.2 mm vs. 6.2 ± 2.5 mm, p = 0.008). CONCLUSION: Pre-placement of pancreatic duct stents significantly enhances enucleation success rate, reduces hospital stays, preserves pancreatic function, and improves quality of life. These findings advocate the use of pre-placed stents in enucleation procedures. Further prospective studies are warranted to validate these outcomes.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Hu B, Yin Y, Liu C, et al. Optimizing pancreatic enucleation for benign tumors: the role of pre-placed pancreatic duct stents-a retrospective cohort study. Surg Endosc. 2025. PMID: 40325247. doi:10.1007/s00464-025-11748-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。